BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Second Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study

  The approval allows two U.S. sites, the University of California at Los Angeles (UCLA) and Baylor College of Medicine (Baylor) in Houston, to enroll up to five total patients.

  November 2, 2017

   · 

  6 min read
• Biotech Bay

  BioCardia Announces Reverse Stock Split and Release of Indemnity Holdback Shares

  The company’s common stock will begin trading on a split-adjusted basis when the markets open today under the existing trading symbol “BCDA”.

  November 2, 2017

   · 

  6 min read
• 

  Pharm Country

  Late-Stage Life Sciences Investment Firm, Aisling Capital, Closes $280M Fund

  Aisling Capital today announced the closing of its newest fund, with $280M in committed capital.

  November 2, 2017

   · 

  2 min read
• 

  Drug Development

  FDA Sticks Breakthrough Tag on GlaxoSmithKline’s Blood Cancer Drug

  GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.

  November 2, 2017

   · 

  4 min read
• Business

  VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

  VolitionRX today announced it will host a conference call on Friday, November 10 at 8:30 a.m.

  November 2, 2017

   · 

  3 min read
• Policy

  Perrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato Gel 0.05%

  The submission date of Perrigo’s ANDA matches the first-to-file date posted on FDA’s Paragraph IV Patent Certifications list.

  November 2, 2017

   · 

  4 min read
• Business

  Therapix Biosciences’ Board Chairman, Ascher Shmulewitz, Appointed as Interim CEO

  Therapix has appointed Ascher Shmulewitz, M.D., Ph.D., the Company’s Chairman of the Board of Directors, to the role of Interim CEO, effective immediately.

  November 2, 2017

   · 

  4 min read
• Drug Development

  Concentric Analgesics Launches CA-008 Clinical Development Program in Post-Surgical Pain

  Results from this clinical trial are expected in the first quarter of 2018.

  November 2, 2017

   · 

  3 min read
• Business

  PURE Bioscience Expands Board of Directors With Appointment of Elisabeth Hagen, M.D., Food Safety Consultant

  Dr. Hagen joins as an independent director, expanding the six-person Board to seven members.

  November 2, 2017

   · 

  4 min read
• BioMidwest

  DowDuPont Declares Quarterly Dividend of 38 Cents per Share, Announces Initial $4 Billion Share Repurchase Program

  DowDuPont’s dividend for the fourth quarter of 2017 will be payable on Dec. 15, 2017, to shareholders of record on Nov. 15, 2017.

  November 2, 2017

   · 

  8 min read